Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Overactive Bladder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    116 result(s) found for: Overactive Bladder. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2005-004499-19 Sponsor Protocol Number: 0634-007 Start Date*: 2005-11-22
    Sponsor Name:Merck Sharp & Dohme Ireland (Human Health) Limited
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of L-000796568 in Postmenopausal Women With Overactive Bladder
    Medical condition: Overative Bladder
    Disease: Version SOC Term Classification Code Term Level
    8.0 10059617 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006451-39 Sponsor Protocol Number: A0221046 Start Date*: 2008-02-20
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: 12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENT...
    Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) LT (Completed) ES (Completed) HU (Completed) GR (Completed) EE (Completed) LV (Completed) SK (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-001452-39 Sponsor Protocol Number: 178-CL-049 Start Date*: 2008-06-05
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Randomized, Double-Blind, Parallel Group, Active Controlled, Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Sy...
    Medical condition: Symptoms of overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed) IS (Completed) CZ (Completed) LV (Completed) IE (Completed) GB (Completed) BE (Completed) FR (Completed) ES (Completed) DK (Completed) LT (Completed) SK (Completed) PT (Completed) NL (Completed) IT (Completed) HU (Completed) AT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-005736-29 Sponsor Protocol Number: 178-CL-102 Start Date*: 2014-07-08
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to S...
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) HU (Completed) IT (Completed) FI (Completed) GB (Completed) EE (Completed) SE (Completed) SK (Completed) CZ (Completed) LV (Completed) DK (Completed) SI (Completed) PL (Completed) ES (Completed) LT (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-001243-30 Sponsor Protocol Number: 840 30 40 Start Date*: 2004-12-09
    Sponsor Name:Apogepha Arzneimittel GmbH
    Full Title: Propiverine hydrochloride in children suffering from overactive bladder and urinary incontinence. A randomised, double-blind, placebo-controlled, parallel grouped multicentre clinical trial.
    Medical condition: children suffering from overactive bladder and urinary incontinence
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) AT (Completed) SE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011418-68 Sponsor Protocol Number: CSO302L Start Date*: 2009-10-14
    Sponsor Name:GlaxoSmithKline Consumer Healthcare GmbH & Co. KG
    Full Title: Pilotstudie zur Anwendung eines pflanzlichen Kombinationspräparats bei Frauen mit Reizblase ("Overactive Bladder"-Syndrom). (Translation: Pilot-Study with a herbal combination in women suffering f...
    Medical condition: Frequent micturition and urinary urgency, as common in patients suffering from overactive bladder syndrome.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004126-24 Sponsor Protocol Number: DRI6271 Start Date*: 2007-12-12
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overac...
    Medical condition: Overactive bladder including urge urinary incontinence
    Disease: Version SOC Term Classification Code Term Level
    10.0 10059617 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) PT (Completed) FR (Completed) NL (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000711-24 Sponsor Protocol Number: 2013-000711-24 Start Date*: 2013-10-09
    Sponsor Name:Søren Rittig
    Full Title: The effect of combining anticholinergic treatment and transcutaneous electrical nerve stimulation in children suffering from daytime urinary incontinence and an overactive bladder.
    Medical condition: Daytime urinary incontinence and overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004650-93 Sponsor Protocol Number: botuline5 Start Date*: 2007-10-10
    Sponsor Name:University Medical Center Groningen
    Full Title: The effect of Botulinum toxin A injections for overactive bladder on detrusor contractility
    Medical condition: Neurogenic or idiopathic overactive bladder, not adequately responding to anticholinergic therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005713-37 Sponsor Protocol Number: 178-EC-001 Start Date*: 2012-04-05
    Sponsor Name:Astellas Pharma Europe Ltd
    Full Title: A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects with Overactive Bladder (OAB) Treated with Antim...
    Medical condition: Overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FI (Completed) CZ (Completed) SE (Completed) DE (Completed) ES (Completed) GB (Completed) SK (Completed) AT (Completed) BE (Completed) NO (Completed) GR (Completed) HU (Completed) DK (Completed) LV (Completed) NL (Completed) PT (Completed) PL (Completed) LT (Completed) SI (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001451-19 Sponsor Protocol Number: 178-CL-046 Start Date*: 2008-06-05
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with ...
    Medical condition: Symptoms of Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed) IS (Completed) CZ (Completed) LV (Completed) IE (Completed) GB (Completed) BE (Completed) FR (Completed) ES (Completed) HU (Completed) DK (Completed) LT (Completed) PT (Completed) IT (Completed) NL (Completed) AT (Completed) GR (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-005457-22 Sponsor Protocol Number: TA-5538-03 Start Date*: 2006-03-30
    Sponsor Name:Tanabe Seiyaku Co., Ltd
    Full Title: A phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladder
    Medical condition: A phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) FI (Completed) HU (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004590-28 Sponsor Protocol Number: 1207.5 Start Date*: 2005-04-06
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: Efficacy and safety of 40 mg, 80 mg and 160 mg KUC 7483 BS administered twice daily and 160 mg administered once a day over 8 weeks in patients with overactive bladder syndrome (a double-blind, pla...
    Medical condition: Patients aged 18-75 years, of both sexes with symptoms of overactive bladder syndrome for at least 6 months. Lower level term (LLT): Overactive bladder (10059617) System Organ Class: Renal and Uri...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10059617 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004124-23 Sponsor Protocol Number: A0221058 Start Date*: 2009-01-29
    Sponsor Name:Pfizer Limited
    Full Title: A 12 week, multicentre, open label study to evaluate the efficacy, tolerability and safety of a Fesoterodine flexible dose regimen in patients with overactive bladder
    Medical condition: Treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur in patients with overactive bladder syndrome.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000833-36 Sponsor Protocol Number: STH14330 Start Date*: 2007-12-14
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: The Action of Botox® on Urgency – A precise evaluation of its impact on urodynamic parameters during bladder filling in patients with non-neurogenic Overactive Bladder (OAB).
    Medical condition: Non-neurogenic Overactive Bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005606-23 Sponsor Protocol Number: 0594-003 Start Date*: 2006-03-24
    Sponsor Name:Merck Sharp and Dohme de España
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder Estudio multicéntrico, doble ciego, aleato...
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    8.0 10059617 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SE (Prematurely Ended) DK (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002047-10 Sponsor Protocol Number: 905-CL-077 Start Date*: 2012-11-01
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects with Overactive Bladder (OAB)
    Medical condition: Overactive Bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) NL (Completed) DE (Prematurely Ended) DK (Completed) SE (Completed) NO (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-003398-24 Sponsor Protocol Number: OAB/AB/07 Start Date*: 2008-01-21
    Sponsor Name:The Whittington Hospital NHS Trust
    Full Title: A randomised, double blind validation of the significance of occult pyuria for the symptoms of the overactive bladder
    Medical condition: The overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000893-19 Sponsor Protocol Number: NIHR 2007 OAB 0507 Start Date*: 2008-07-29
    Sponsor Name:Whittington NHS Trust
    Full Title: A randomised, double blind, placebo controlled, crossover trial of the adjuvant properties of imipramine for the overactive bladder.
    Medical condition: Overactive bladder symptoms
    Disease: Version SOC Term Classification Code Term Level
    1 10059617 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006935-38 Sponsor Protocol Number: A0221008 Start Date*: 2007-04-16
    Sponsor Name:Pfizer Inc. NYO-685-21-14,685 3rd Avenue, NEW YORK, NY 10017. US
    Full Title: 12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENT...
    Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) BE (Completed) HU (Completed) DK (Completed) CZ (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 15:30:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA